Larry Wolfraim | Vaccine Product Development Project Officer
Biodefense Vaccines & Other Biolgl Product Dvpmt Sect (HNM5C2)

Larry Wolfraim, Vaccine Product Development Project Officer, Biodefense Vaccines & Other Biolgl Product Dvpmt Sect (HNM5C2)

Dr. Wolfraim earned his PhD at McGill University and completed a postdoctoral fellowship in Marburg, Germany before becoming an intramural scientist at NCI. From there, Dr. Wolfraim entered industry, most notably working as the Principal Investigator at DynPort Vaccines Ltd on NIAID funded tularemia vaccine contracts, as well as a DoD supported plague vaccine in late stage clinical development. Dr. Wolfraim has served for the past 7 years a Program Officer in NIAID’s Division of Microbiology and Infectious Diseases, in the Biodefense Vaccines and other Biological Products Development Section of the Office of Biodefence, Research Resources and Translational Research. He serves as the Contracting Officer’s Representative (COR) on NIAID’s IDIQ Preclinical Services contract for the evaluation and testing of vaccines.

Appearances:



Pre-congress Workshops, April 6 @ 10:00

WORKSHOP E (FULL DAY): BIODEFENCE

The role of vaccines in preventing outbreaks, through natural causes or biothreatsIt only takes natural outbreaks and bioterrorism attacks like the Ebola and anthrax to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.
  • NIAID’s gap filling preclinical services for vaccine development
  • Expanding the utility of biodefense vaccines
  • Biodefense and Pandemic Preparedness:Two sides of the same coin?
  • Update on the broadly neutralizing influenza monoclonal antibody used for the DARPA-funded Pandemic Preparedness Platform (P3) initiative
  • A disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
Moderator: Matthew Hepburn, Program Manager, D.A.R.P.A.
Benjamin Petsch, Senior Director Infectious Diseases Research, CureVac AG
Nicole Kallewaard, Associate Director, Microbial Sciences, AstraZeneca
Robert Fisher, Senior Advisor for CBRN and Pandemic Influenza, Office of Counterterrorism and Emerging Threats (OCET), Food and Drug Administration (FDA)
Daniel Wolfe, Project Officer, Biomedical Advanced Research And Development Authority
Larry Wolfraim, Vaccine Product Development Project Officer, Biodefense Vaccines & Other Biolgl Product Dvpmt Sect (HNM5C2)
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates